AstraZeneca (AZN) announces $3.5B of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the end of 2026. This includes $2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy. AstraZeneca’s expanding footprint in the US includes, among others: A research and development, R&D, center in Kendall Square, Cambridge, Massachusetts; A next generation manufacturing facility for biologics in Maryland; Cell therapy manufacturing capacity on the West and East Coasts; Specialty manufacturing in Texas. Pascal Soriot, Chief Executive Officer, AstraZeneca said: “Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- AstraZeneca reports Q3 core EPS $2.08, consensus $1.03
- AstraZeneca now sees FY24 core EPS to increase by high teens percentage
- Tectonic Therapeutic price target raised to $69 from $49 at Leerink
- Options Volatility and Implied Earnings Moves This Week, November 11 – November 15, 2024
- QQQ ETF Update, 11/11/2024
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
